Island Pharmaceuticals Limited (ILA.XA)
Cboe AU · AUD
A$0.31 (+0.00%) as of
Key statistics
- 52-week range
- 0.2950 – 0.6300
- Beta
- 0.17
- Revenue (TTM)
- 282.66k
- Profit margin
- 0.00%
- Volume
- 24.39k
About Island Pharmaceuticals Limited
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States. The company's lead product candidate is ISLA-101, a drug which is in second clinical-stage for the prevention and treatment of dengue fever and other mosquito vector borne diseases; and Galidesivir, a spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.
- Headquarters
- Hawthorn East, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.